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Abstract 
Prevention of colorectal cancer by colonoscopy requires effective and safe insertion technique, high 
level detection of precancerous lesions, and skillful use of curative endoscopic resection techniques. 
Lesion detection, characterization, use of appropriate resection methods, prediction of cancer at 
colonoscopy, and management of malignant polyps, all depend on an accurate and complete 
understanding of an extensive vocabulary describing the histology and morphology of neoplastic 
colorectal lesions.  Incomplete understanding of vocabulary terms can lead to management errors.  We 
provide a colonoscopist’s perspective on the vocabulary of colorectal neoplasia, and discuss the 
interaction of specific terms with management decisions. 
Introduction 
About 60% of the eligible U.S. population report having undergone colonoscopy in the last 10 years (1). 
Many gastroenterologists spend more time performing colonoscopy than on any other professional 
activity.  One would expect gastroenterologists to be expert in all aspects of the vocabulary of colorectal 
neoplasia, including  histologic and morphologic classifications of polypoid and flat lesions. 
However, speaking to groups of gastroenterologists and other endoscopists, one is often surprised 
about the responses to fundamental questions about colorectal neoplasia. For example, how reliable is a 
pathologist's designation of dysplasia grade in a conventional adenoma? Why is the term "dysplastic 
adenoma" redundant? Why should the term "intramucosal adenocarcinoma" not be used in pathology 
reports? What is the histologic difference between a hyperplastic polyp and a sessile serrated 
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polyp/adenoma? What are the implications of granular versus non-granular morphology in a lateral 
spreading tumor? What is the histologic definition of colon cancer?  
 
The answers to these and similar questions provide colonoscopists with critical insights into the 
limitations of pathology, the proper responses to pathologic interpretations of colon polyps, and in 
many cases to optimal endoscopic, clinical, or surgical management. A detailed understanding of the 
implications of both endoscopic appearances and histology is critical in guiding the colonoscopist.  The 
modern expert colonoscopist is able to use electronic chromoendoscopy techniques and established 
classification schemes to predict lesion histology. Thus, an expert colonoscopist is able to differentiate 
between a serrated and adenomatous polyp, and between a deeply invasive cancer versus superficial 
colorectal neoplasia. This review provides a clinically oriented framework to the vocabulary surrounding 
the main classes of colorectal lesions, particularly the conventional adenomas and serrated lesions. It 
also stresses the implications of this vocabulary on management and follow-up, including how the 
endoscopic assessment of histology and morphology direct the selection of specific therapies such as 
endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD) and surgical resection. 
 
 
1. What are EMR and ESD? 
 
Endoscopic mucosal resection (EMR) refers to submucosal fluid injection followed by en bloc or 
piecemeal snare resection.  EMR is easier to perform than ESD (endoscopic submucosal 
dissection), requires less training, has a much lower risk of perforation, and a lower need for 
hospitalization post resection. EMR may be technically quite difficult when lesions are very 
large, very flat, in a technically challenging position or when they are accompanied by 
submucosal fibrosis.  Both EMR and ESD have substantial risks of delayed post-polypectomy 
hemorrhage.  For these reasons many colorectal lesions that are benign and removable by EMR 
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are sent directly to surgery in the United States and Europe (2,3), even though surgery results in 
higher costs,  morbidity, and mortality compared with EMR (4-6). 
 
ESD was developed in Japan to treat early gastric cancer.  ESD has been extended to the colon, 
where it has been used successfully by Japanese experts (7-9) and increasingly by western 
experts (10-12).  The technique comprises submucosal injection, but ESD does not use snare 
resection.  Rather, specialized endoscopic needle-like knives are used to create a circumferential 
incision through the mucosa around the lesion, followed by dissection through the submucosa 
under the lesion. The goal of ESD is en bloc resection in all cases, and ESD is much more likely 
than EMR to achieve this result (13).  The en bloc tissue specimen is pinned before fixation to 
provide  proper orientation for pathologic assessment of the deep and lateral resection margins.  
Whether ESD should be used more extensively in the west is controversial.  Given the 
advantages of EMR relative to ESD noted above, which patients and how many patients really 
benefit from ESD compared with EMR is a critical issue that is discussed in detail below. 
 
2. The colonoscopist’s vocabulary of colorectal cancer   
Because the colon has no mucosal lymphatics, colon cancer is defined in western countries as invasion 
of dysplastic cells into the submucosa. It follows that any neoplastic lesion that is confined to the 
mucosa – including epithelium, lamina propria and muscularis mucosa – must be considered  pre-
cancerous or “non-invasive,” irrespective of its dysplastic or cytological appearance, and is best named 
as low or high-grade dysplasia. Some pathologists still use terms such as "carcinoma in situ" and 
"intramucosal adenocarcinoma" to describe lesions involving severe dysplastic changes confined to the 
epithelium or  lamina propria, respectively. However, these terms are often misinterpreted by patients, 
referring physicians, and sometimes by colonoscopists, as cancer because they include the word 
"carcinoma." This confusion can result in unnecessary surgery or excessive follow up for a lesion that is 
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benign by definition. Such  lesions have no lymph node or distant metastatic potential because they lack 
submucosal invasion, and complete endoscopic resection is uniformly curative. Current U.S. National 
Comprehensive Cancer Center Network (NCCN) guidelines specifically state, “A malignant polyp is 
defined as one with cancer invading through the muscularis propria and into the submucosa (pT1). PTis 
is not consider a “malignant polyp.”  
[https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf]." We recommend that 
colonoscopists meet with their pathologists to reach consensus regarding optimal terminology, and that 
colonoscopists take the position that pathologists report “high-grade dysplasia” and not use the terms 
“intramucosal carcinoma” or “carcinoma-in-situ,” in order to reduce the potential for clinical 
management errors (Table 2).  Western colonoscopists may be also confused because Japanese 
pathologists and gastroenterologists commonly use the term “intramucosal carcinoma” and count it as 
cancer. This difference is related to cultural and economic issues, whereas no clinical difference is 
present, ie, endoscopy is still considered completely adequate treatment for such lesions in Japan. We 
recommend that in western countries the terms “carcinoma in situ” and “intramucosal carcinoma”  be 
abandoned because they may lead to incorrect patient management. Terminology should serve patients 
and physicians by optimizing rather than confusing management and hence the term cancer is reserved 
(in the colorectum) in western countries exclusively for submucosal invasion.   
 
 
3. What is superficial versus deep submucosal cancer?  
 
When submucosal cancer is present in a pedunculated polyp, endoscopy is usually regarded as an 
adequate treatment when three histological factors, namely cancer at the resection margin, lympho-
vascular invasion, and poor differentiation, are absent (13). When invasive cancer is present in a flat (ie, 
non-polypoid) or sessile lesion, the depth of invasion below the muscularis mucosa (MM) should be 
measured by the pathologist, when technically feasible. If the depth is <1000 microns, the submucosal 
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cancer is classified as "superficial." If the depth of invasion is >1000 microns, the cancer demonstrates 
"deep submucosal invasion." There are elements of subjectivity with this measurement as the MM layer 
may be disrupted or not visible. Reliable measurement of the depth of invasion is generally considered 
to require en bloc resection of the lesion by conventional snare techniques for smaller lesions and either 
en bloc EMR or ESD for lesions greater than 10 to 20 mm. Pinning the lesion to allow proper orientation 
for histologic sectioning is important (12,13). When after an en bloc resection, a superficial submucosal 
cancer does not present lympho-vascular invasion or poor differentiation, endoscopic treatment may be 
considered as adequate, due to a very low risk of lymph-node metastasis. Contrarily, the risk of lymph 
node metastasis increases substantially when deep submucosal invasion is present.  
 
When deep submucosal invasion is predicted by endoscopic features (15), it is preferable to avoid 
endoscopic resection and proceed to surgery.  This prevents the risk of endoscopic adverse events, and 
endoscopic resection followed by pathology demonstrating deep submucosal invasion will result in 
surgery in any case.  If superficial invasion is identified after piecemeal snare resection of a flat or sessile 
lesion, surgical resection is often still considered because of the risk of under-staging a potentially 
deeply invasive cancer, especially if adequate orientation of the specimen by the pathologist is not 
feasible. This difference highlights the benefit of en bloc resection.  With en bloc resection of a sessile or 
flat lesion and proper specimen orientation, the patient with superficial invasion (and lacking other 
adverse histologic features) has the option of relying on endoscopic resection alone, as the risk of lymph 
node metastasis is very low (though not zero). In the West many patients in this situation, especially if 
they are young (eg, <60 years old) and healthy, will select surgical resection even when all histologic 
criteria associated with submucosal invasion are favorable, because the risk of metastasis with favorable 
criteria is very low but not zero. Again, when the same lesion has been treated by piecemeal snare 
resection, confidence in whether adequate treatment has been provided by endoscopy is undermined.   
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Endoscopic predictors of deep (>1000 microns) submucosal invasion in flat and sessile lesions are 
described in the Type 3 category of the NICE classification (15,16) (Table 1). Identification of NICE Type 3 
features in a flat or sessile lesion is generally an indication for surgical resection (Figure 1).  If surgery is 
planned the NICE 3 area can be biopsied to confirm invasive cancer.  In Japan reliance on NICE alone to 
endoscopically predict cancer is considered inadequate, because the magnifying endoscopes widely 
used in Japan can identify features that extend the predictions achievable with the high-definition 
instruments commonly in use in North America and Europe.  These features are summarized in the 
Japan NBI Expert Tean (JNET) classification for magnifying colonoscopy (17).  Widespread use of the 
JNET classification in the west, where magnifying colonoscopes are not widely used, is not anticipated in 
the near future.  
 
Unfortunately, no reliable endoscopic features  differentiate superficial submucosal invasion from high-
grade dysplasia (15,16)  However,  some endoscopic morphologic features are associated with higher 
risk of submucosal invasion, namely nongranular lateral spreading tumors (LSTs), particularly those with 
a focal depressed component, and to a lesser extent large mixed-type granular lesions (granular lesions 
with nodules) (18). The term “LST” refers to a flat or sessile lesion with a diameter of at least 1 cm (19).  
The morphology of LSTs and its association with invasive cancer is discussed in more detail below. 
 
 
As noted above, patients that benefit from ESD rather than piecemeal EMR are those with superficial 
submucosal invasion that cannot be removed en bloc by EMR. In European series, this group is about 2% 
to 3% of patients referred for resection of large colorectal lesions (10-12).  In Japanese series 7% to 10% 
of colorectal lesions subjected to ESD have superficial invasion, reflecting better patient selection for 
ESD (higher fraction of non-granular LSTs) (7-9).  Nongranular LSTs >20 mm in size (en bloc excision by 
EMR is generally limited to lesions ≤20 mm) with focal depression and lacking NICE Type 3 features are 
the best candidate group for ESD in the colorectum, as they have the highest rate of superficial 
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submucosal invasion. EMR can still be used to treat these lesions, but the patient may be referred for 
surgery if there is submucosal invasion, regardless of the depth of invasion. 
 
4. The  vocabulary of conventional adenomas  
The main histologic classes of precancerous colorectal neoplasia are the conventional adenomas and the 
serrated class lesions (Figure 2). Pathologists are generally accurate in assigning lesions to the 
conventional adenomas versus the serrated class (20). Experienced colonoscopists are also effective at 
predicting the histologic class of specific lesions using criteria such as NICE (Table 1).  
 
Pathologists subclassify conventional adenomas according to the dysplasia grade (low versus high is the 
proper designation; mild-moderate-severe is out dated), and tubular versus villous elements. Although 
the placement of lesions into the conventional adenoma category by the pathologist is reliable, the 
subclassifications are unreliable (20). Stated differently, they are subject to substantial interobserver 
variation (Table 3), and this is particularly true in their application to polyps <1 cm in size (21). This size 
group is of particular relevance because polyps ≥1 cm in size are considered advanced lesions based on 
their size alone, whereas lesions <1 cm in size are not advanced unless they have either high-grade 
dysplasia or villous elements. The overwhelming majority of adenomas are tubular, that is they contain 
≥75% tubular elements. Using identical definitions, pathologists vary by up to 6-fold in the frequency 
with which they call polyps tubulovillous (21). Problems with dysplasia grade interpretations are even 
greater because there is no clear consensus on the definition of high-grade histology (21). Pathologists 
who read high percentages of lesions with high-grade dysplasia are typically using cytologic criteria in 
addition to morphologic criteria. Any reading of high-grade dysplasia in a conventional adenoma <1 cm 
in size is suspect, and may not withstand review by another or an expert gastrointestinal pathologist 
(21). Currently, there are no reliable endoscopic criteria to differentiate dysplasia grade or villousity in a 
conventional adenoma, so colonoscopists must rely on the interpretation by pathologists. However, the 
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expected prevalence of villous elements and high-grade dysplasia in 6 to 9 mm lesions is quite low, and 
even lower in conventional adenomas ≤5 mm in size (22). The unreliability of pathologic interpretation 
of dysplasia grade and villousity is such that the British Society of Gastroenterology ignores these 
elements in their postpolypectomy surveillance guideline (23).  
 
Although diagnoses of dysplasia grade and villousity are subject to marked interobserver variation 
between pathologists, these factors are included as determinants of surveillance intervals in clinical 
guidelines.  As noted above, the appropriateness of using these factors as surveillance determinants is 
controversial.   
Using the NICE classification, expert colonoscopists can predict adenomatous versus serrated class 
histology with an accuracy similar to pathologists. This approach forms the basis of new paradigms for 
diminutive polyp management, including the “resect and discard” scheme and leaving distal colon 
diminutive hyperplastic appearing polyps in place without resection (24).  Predicting adenomatous 
histology endoscopically is also important to the therapeutic colonoscopist.  Specifically, the adenomas 
are a more challenging group of lesions to resect than the serrated lesions (see below).  The adenomas 
can become very large (nearly circumferential and extending longitudinally over multiple haustral folds).  
The non-granular LSTs and the depressed class of lesions are almost entirely adenomas.  Adenomas are 
much more likely to have submucosal fibrosis compared with serrated lesions, and submucosal fibrosis 
is the bane of EMR.  Serrated lesions present their own set of obstacles to endoscopic resection (24), but 
they are usually easily overcome. 
5. The  vocabulary of serrated lesions  
The “serrated class” includes 3 distinct groups of lesions: hyperplastic polyps, sessile serrated polyps 
(also called sessile serrated adenomas), and traditional serrated adenomas (TSA) (26) (Figure 2).  TSAs 
are rare by comparison with the other 2 serrated class subtypes.  TSAs are located mostly in the left side 
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of the colon, are usually sessile, and are the only group of serrated class lesions that is consistently 
dysplastic (27).  Because they grow in a villous pattern and are dysplastic, TSAs may be interpreted by 
pathologists as tubulovillous adenomas (27). This error appears to be made so consistently by some 
pathologists that colonoscopists often anecdotally report never seeing TSA on a pathology report.  
Because TSAs are rare, we will focus here on the hyperplastic polyps and sessile serrated 
polyp/adenoma, both of which are quite common. 
 As stated earlier, both pathologists and colonoscopists accurately place polyps into the conventional 
adenoma versus serrated class (with the exception of TSA). Unlike the conventional adenomas and TSAs, 
all of the hyperplastic polyps and the overwhelming majority of sessile serrated polyps (SSP) are non-
dysplastic (27). Sessile serrated polyp (SSP) is synonymous with sessile serrated adenoma (SSA) (26), but 
we prefer “sessile serrated polyp” in conversation and on pathology reports.  This preference is because 
clinicians interpret the word "adenoma" to signify dysplasia (as noted above, all conventional adenomas 
are dysplastic).  Thus, clinicians often believe that a “sessile serrated adenoma” must be dysplastic.  
Since, in fact, the great majority of these lesions are not dysplastic, we feel “SSP” causes less confusion 
for clinicians.  Despite this preference, we acknowledge that neither “SSP” nor “SSA” is ideal from the 
perspective that many of these lesions are flat and not polyps (both terms contain the word “sessile”), 
and “SSP” could compound this confusion by including the word “polyp.”  Regardless of which term (SSP 
vs SSA) is used clinicians must understand that (1) SSP and SSA are synonyms, (2) these lesions can be 
either sessile or flat, and (3) these lesions are usually not dysplastic.  To further acknowledge that SSP 
and SSA are synonyms, we refer to the lesions here by the commonly accepted acronym “SSA/P” (27).    
 
The histologic differentiation of a hyperplastic polyp (HP) from an SSA/P rests primarily on the shape of 
crypts (27).  SSA/Ps have crypts that are dilated, distorted, or demonstrate lateral growth, whereas the 
crypts of hyperplastic polyps are straight. Unfortunately, no definition of the extent to which the crypts 
should be distorted has been validated as having clinical significance in distinguishing a group of polyps 
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(SSA/Ps) with malignant potential and distinct behavior from hyperplastic polyps. Further, different 
histologic criteria for SSA/P are in use. For example, the World Health Organization (WHO) recommends 
that three abnormal crypts constitute a diagnosis of SSA/P (26), whereas an NIH consensus panel 
recommended that one unequivocally abnormal crypt is diagnostic of SSA/P (27), and the Japanese 
Pathology Society recommends that ≥10% of the crypt be affected to diagnose SSA/P (28). When the 
number of crypts affected by distortion is small, there is substantial interobserver variation in 
differentiating HP from SSP (29).  
 
Although the overwhelming majority of SSA/Ps have no cytological dysplasia (Table 3), a small 
percentage contain a region that looks like a conventional adenoma (Figure 3). In decades past, this 
lesion was  designated a "mixed hyperplastic-adenomatous polyp," which was perfectly logical because 
these polyps contain regions that endoscopically and histologically correspond to the serrated class and 
the conventional adenoma class, respectively. The dysplastic area in an SSA/P is the portion with 
histologic features of a conventional adenoma and which endoscopically has NICE Type 2 features, 
whereas the remainder of the polyp is NICE Type 1 (30) (Figure 4). Any dysplasia (low-grade or high-
grade) in an SSA/P constitutes a more advanced lesion than an SSA/P without cytological dysplasia (27), 
and one which could progress rapidly to cancer (31). The area of dysplasia often demonstrates 
microsatellite instability in microdissection studies (32).  
 
Endoscopic criteria for differentiation of HP from SSA/P have been proposed and validated in the WASP 
classification (33)(Table 4, Figure 5), but their accuracy in differentiating HP from SSA/P in diminutive 
size lesions is not established. Given the substantial  interobserver variation in distinguishing SSA/P from 
HP pathologically, and because the prevalence of SSA/P increases with lesion size, any proximal colon 
serrated class lesion ≥1 cm in size and interpreted  pathologically as hyperplastic, can be reasonably 
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treated for surveillance purposes as an SSA/P (34).  This approach is particularly appropriate if the lesion 
had endoscopic features of SSA/P (33).   
 
Diminutive NICE Type 1 lesions in the rectosigmoid are almost entirely hyperplastic (35), which is the 
rationale for leaving them in place (24). For the therapeutic colonoscopist, the key feature of SSA/Ps is 
their endoscopically indistinct edges, which often leads to incomplete resection using traditional 
polypectomy techniques (snaring without submucosal injection).  This problem is easily overcome by 
submucosal injection of a contrast agent and use of a high-definition colonoscope, which in combination 
allow easy tracking of the perimeter during resection (36,37).  The size threshold for performing 
submucosal injection in SSA/Ps should be 10 to 15 mm (38). Piecemeal cold snare excision of non-
dysplastic SSA/P, which is facilitated by submucosal injection, is an evolving area of interest. Cold 
resection largely prevents the risks of EMR.  ESD is unnecessary for serrated lesions, because they 
almost universally lack invasive disease unless endoscopic features of dysplasia, large nodules or 
depressed areas are present.  
6. The vocabulary of polyp morphology  
The morphology of colon polyps is of great importance to colonoscopists, and to a lesser degree to 
pathologists. The Paris classification provides a useful framework for discussing polyp shape and  
emphasizes the subtle nature of flat lesions (Figure 6). Training in the Paris classification should be  
included in all endoscopic training as an enhancement to detection.   Interobserver agreement in 
assigning lesions to Paris classification categories is moderately good at best (39), but still the 
classification provides a useful clinical framework for discussing morphology.   
 
Paris type I lesions are polyps. Paris type II lesions include flat (types IIa and IIb) and depressed (IIc and 
its variants) lesions.  High detecting colonoscopists find such large numbers of diminutive flat adenomas 
that IIa and Is lesions are present in approximately equal numbers (40).   The Paris IIc depressed lesions 
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are both rare and enormously important because of their very high prevalence of high-grade dysplasia 
and cancer relative to all other morphologies (41). The prevalence of cancer in both Paris Type I and IIa 
lesions is extremely low, whereas the prevalence of high-grade dysplasia and cancer in IIc lesions can 
reach 50% (38).  Depression is characterized by a sharp drop off from the elevated to depressed 
portions, and the total area of the depression is substantial. Much more common is the "IIa 
pseudodepression," which has sloping edges and usually occupies a much smaller surface area, and does 
not extend down to or below the level of the normal mucosa adjacent to the lesion. Unlike true 
depressions, pseudodepressions have no importance as a predictor of advanced histology.  
 
If a depressed lesion presents features suggestive of advanced cancer, such as ulceration or amorphous 
vascular pattern, these lesions should undergo biopsy and then surgery. On the other hand, if the 
surface pattern is preserved, en bloc resection should be considered, in order to provide adequate 
staging and treatment for a possible superficial submucosal cancer. 
 
Flat lesions extending >1 cm in diameter are designated in the Paris classification as lateral spreading 
tumors (LSTs), and they may have a sessile  component (mixed LST). They are sometimes now called 
lateral spreading lesions as term “tumor” can be misinterpreted to mean invasive disease, and in years 
past were called "carpet polyps." LSTs are further characterized as granular, which have a lumpy, bumpy 
surface (Figure 7) or "non-granular," which have a smooth surface. Chromoendoscopy enhances the 
surface features and can clarify granular versus non-granular morphology.  The significance of granular 
and non-granular is demonstrated in Table 5. Homogeneous granular lesions (like the surface of a bowl 
of rice crispies) have an extremely low prevalence of invasive disease at <1%. These lesions grow 
laterally, sometimes for very long periods of time, and a risk of invasive disease is acquired when a 
nodule develops (granular LST mixed-nodular type). Nodules in granular LSTs are associated with an 
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approximately 5% risk of invasive cancer (18) (Table 5). Non-granular lesions can be difficult to resect by 
EMR because they have a high prevalence of submucosal fibrosis and often a low mucosal profile that 
may defy snare capture. The prevalence of cancer is higher in non-granular LSTs, particularly those with 
depression. Again, a non-granular LST with depression that lacks NICE Type 3 features is the best clinical 
indication for ESD over EMR.  
 
The terms granular and non-granular LST are used for LSTs of the conventional adenoma class. This 
classification has no proven benefit in describing large SSA/Ps, which have different surface features 
from  adenomas.  Large SSA/Ps are flat or sessile in shape, almost never have significant fibrosis in the 
submucosa, and rarely contain cancer in the absence of overt morphologic features of a dominant 
nodule, depression or ulceration (42).  
 
 
 
7. Putting it all together  
 
Table 6 summarizes clinically relevant information regarding the pre-cancerous colorectal polyps.    
Effective colonoscopic withdrawal technique has 3 basic components, including continuous effort to 
examine the proximal sides of haustral folds, achieving adequate distention, and cleaning the mucosal 
surfaces (42). However, the mechanical aspects of withdrawal technique must be combined with 
complete understanding of the spectrum of precancerous colorectal lesions. This understanding guides 
the approach and eyes of the colonoscopist. Thus, a full understanding of the Paris classification ensures 
awareness of the large pool of subtle lesions.  
 
Table 6 shows that the distribution of the Paris Type 2 lesions, whether conventional or serrated, is 
skewed toward the proximal colon. The skewed distribution of flat and depressed lesions toward the 
proximal colon may partly account for why colonoscopy fails to protect against proximal colon cancer as 
well as distal cancers (44,45).  Detailed understanding of disease spectrum and meticulous technique 
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lead to high ADRs.  In the resection phase, understanding the implications of lesion morphology is 
essential to correct decisions. For example, SSA/Ps are less effectively removed by standard snaring 
techniques because of their indiscrete edges. At a relatively low size threshold, EMR with a contrast 
agent permits effective SSA/P resection. Further, SSA/Ps almost never have significant submucosal 
fibrosis, making EMR straightforward.  If an LST is recognized endoscopically as a conventional adenoma, 
it is further classified as granular versus nongranular. Granular lesions have little or no submucosal 
fibrosis, and again, EMR will be relatively easy. Nongranular tumors have an increased risk of both 
cancer and submucosal fibrosis, and the knowledgeable colonoscopist anticipates the need for specific 
methods to counter submucosal fibrosis, (eg, avulsion (46)). Nongranular lesions demonstrating true 
depression have a higher risk for cancer, and ESD may be warranted if available. For both granular and 
nongranular tumors, the surface of the lesion should be carefully evaluated for NICE type III features, 
which should lead to endoscopic biopsy and then surgery.  
 
Understanding clinically relevant histology guides post resection management. Knowing that 
“intramucosal adenocarcinoma" and “carcinoma-in-situ” are not actually cancer, the colonoscopist will 
recommend to the pathologist that the term high-grade dysplasia be substituted. High-grade dysplasia is 
a benign lesion, and does not warrant overreaction. Thus, a completely resected lesion with high-grade 
dysplasia has been cured.  The informed colonoscopist takes pathologic readings of "villous" and "high-
grade dysplasia" with a grain of salt, particularly in lesions <10 mm, based on high interobserver 
variation between pathologists.  
 
Colonoscopists prefer the term "sessile serrated polyp," but understand that SSP and SSA are 
synonymous terms.   Colonoscopists want SSA/Ps to be designated by pathologists as without or with 
cytological dysplasia. SSA/Ps with cytological dysplasia are often recognized as such endoscopically 
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because of their mixed NICE 1/NICE 2 features. The SSA/P with cytological dysplasia is recognized as a 
more advanced lesion that must be completely resected endoscopically.  
 
To conclude, accurate and thorough understanding of the vocabulary of polyp histology and morphology 
classification are fundamental to the modern colonoscopist's approach to detection, resection, and post 
resection management.  
 
 
 
References: 
1. Sabatino, SS, White, MC, Thompson, TT et al Cancer screening test use – United States, 2013 MMWR 
2015;64:464-8  
2. Luigiano, C, Iabichino, G, Pagano, N et al For “difficult” benign colorectal lesions referred to surgical 
resection a second opinion by an experienced endoscopist is mandatory: A single centre experience 
World J Gastrointest Endosc 2015; 7:881-8 
3. LeRoy, F, Manfredi, S, Hamonic S, et al Frequency of and risk factors for the surgical resection of 
nonmalignant colorectal polyps: a population based study Endoscopy 2016; 48: 263-70 
4. Jayanna, M Burgess NG, Singh, R et al Cost analysis of endoscopic mucosal resection vs surgery for large 
laterally spreading colorectal lesions Clin Gastroenterol Hepatol 2016; 14:271-8 
5. Law R, Das A, Gergory, D et al Endoscopic resection is cost-effective compared with laparoscopic 
resection in the management of complex colon polyps: an economic analysis Gastrointest Endosc 2016; 
83:1248-57 
 
6. Ahlenstiel G, Hourigan LF, Brown G, Zanati S, Williams SJ, Singh R, Moss A, Sonson R, Bourke MJ; 
Australian Colonic Endoscopic Mucosal Resection (ACE) Study Group, Actual endoscopic versus predicted 
surgical mortality for treatment of advanced mucosal neoplasia of the colon. Gastrointest Endosc. 2014 
Oct;80(4):668-76. doi: 10.1016/j.gie.2014.04.015. 
7. Saito, Y, Uraoka, T, Yamaguchi Y et al A multi-center retrospective study of 1,111 colorectal endoscopic 
submucosal dissections (ESD) GIE 2009; 69:AB 114 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
8. Lee, E, Lee JB, Lee SH, et al Endoscopic submucosal dissection for colorectal tumors – 1000 colorectal 
ESD cases: one specialized institute’s experiences Surgical Endoscopy 2013; 27:31-9 
9. Oka, S, Tanaka, S, Saito Y et al  Local recurrence after endoscopic resection for large colorectal neoplasia: 
a multicenter prospective study in Japan Am J Gastroenterol 2015;110:697-707 
10. Spychalski, M, Dziki, A Safe and efficient colorectal endoscopic submucosal dissection in European 
settings: is successful implementation of the procedure possible? Dig Endosc 2015; 27: 368-73 
11. Probst, A. Golger, D, Anthuber, M et al Endoscopic submucosal dissection in large sessile lesions of the 
rectosigmoid: learning curve in a European center Endoscopy 2012; 44: 660-7 
12. Rahmi, G, Hotayt, B, Chaussade, S et al Endoscopic submucosal dissection for superficial rectal tumors: 
prospective evaluation in France Endoscopy 2014;46:670-6 
13. Pimentel-Nunes P, Dinis-Ribeiro, M, Ponchon, T et al Endoscopic submucosal dissection: European 
Society of Gsatrointestinal Endoscopy (ESGE) Guideline Endoscopy 2015; 47:829-54 
14. Williams JG, Pullan RD, Hill J et al Management of the malignant colorectal polyp: ACPGBI position 
statement. Colorectal Dis. 2013 Aug;15 Suppl 2:1-38. 7. 
15. Hayashi, N, Tanaka, S, Hewett, DG et al Endoscopic prediction of deep submucosal invasive carcinoma: 
validation of the narrow-band imaging international colorectal endoscopic (NICE) classification GIE 2013; 
78: 625-32  
16. Hewett, DG, Kaltenbach, T, Sano, Y et al Validation of a simple classification system for endoscopic 
diagnosis of small colorectal polyps using narrow-band imaging; Gastroenterology 2012;143:599-607 
17. Sano, Y, Tanaka, S, Kudo, SE et al  Narrow-band imaging (NBI) magnifying endoscopic classification of 
colorectal tumors proposed by the Japan NBI Expert Team Dig Endosc 2016; 28:526-33 
18. Moss A, Bourke MJ, Williams SJ, et al Endoscopic mucosal resection outcomes and prediction of 
submucosal cancer from advanced colonic mucosal neoplasia. Gastroenterology. 2011 Jun;140(7):1909-
18 gastro.2011.02.062.  
19. Kudo Se, Lambert R, Allen JI,et al. Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointest 
Endosc. 2008 Oct;68 Suppl:S3-47.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
 
20. Rex DK;  Alikhan M, Cummings O  Accuracy of pathologic interpretation of colorectal polyps by general 
pathologists in community practice. Gastrointest Endosc. 1999 Oct;50(4):468-74 
21. Lasisi F1, Mouchli A, Riddell Ret al  Agreement in interpreting villous elements and dysplasia in adenomas 
less than one centimetre in size. Dig Liver Dis. 2013 Dec;45(12):1049-55 
22. Ponugoti PL, Cummings OW, Rex DK  Risk of cancer in small and diminutive colorectal polyps. Dig Liver 
Dis. 2016 Jun 28. pii: S1590-8658(16)30484-4.  
23. Cairns SR, Scholefield JH, Steele RJ, et al Guidelines for colorectal cancer screening and surveillance in 
moderate and high risk groups (update from 2002). ; British Society of Gastroenterology; Association of 
Coloproctology for Great Britain and Ireland;  Gut. 2010 May;59(5):666-89 
24. Rex DK, Kahi C, O'Brien M, et al he American Society for Gastrointestinal Endoscopy PIVI (Preservation 
and Incorporation of Valuable Endoscopic Innovations) on real-time endoscopic assessment of the 
histology of diminutive colorectal polyps.;  Gastrointest Endosc. 2011 Mar;73(3):419-22.  
25. Pohl H, Srivastava A, Bensen SP, et al Incomplete polyp resection during colonoscopy-results of the 
complete adenoma resection (CARE) study. Gastroenterology. 2013 Jan;144(1):74-80. 
26. Snover D, Ahnen DJ, Burt RW, et al Serrated polyps of the colon and rectum and serrated ("hyperplastic") 
polyposis. WHO classification of Tumours Pathology and genetics Tumours of the digestive system. 4th. 
Berlin: Springer-Verlag; 2010. 
27. Rex,D, Ahnen, DJ, Baron, JA et al  Serrated lesions of the colorectum: review and recommendations from 
an expert panel Am J Gastroenterol 2012; 107:1315-29 
28. Yao T, Sugai T, Iwashita A, et al. Histopathological characteristics and diagnostic criteria of SSA/P, project 
research ‘potential of cancerization of colorectal serrated lesions’ of Japanese Society for Cancer of the 
Colon and Rectum. Stomach and Intestine (Tokyo) 2011;46:442–448. (In Japanese) 
29. Khalid, O, Radaideh, S, Cumming, OW et al Reinterpretation of histology of proximal colon polyps called 
hyperplastic in 2001 World J Gastroenterol 2009;15:3767-70 
30. Nanda KS, Tutticci N, Burgess N, Sonson R, McLeod D, Bourke MJ. Caught in the act: endoscopic 
characterization of sessile serrated adenomas with dysplasia. 
Gastrointest Endosc. 2014 May;79(5):864-70. doi: 10.1016/j.gie.2014.01.013. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
31. Bettington M, Walker N, Rosty C, Brown I, Clouston A, McKeone D, Pearson SA, Leggett B, Whitehall V. 
Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma. 
Gut. 2015 Oct 15. pii: gutjnl-2015-310456. doi: 10.1136/gutjnl-2015-310456. [Epub ahead of print] 
32. Sheridan, TB, Fenton, H, Lewin, MR et al Sessile serrated adenomas with low- and high-grade dysplasia 
and early carcinomas: an immunohistochemical study of serrated lesions “caught in the act” Am J Clin 
Pathol 2006; 126:564-71  
33. IJspeert JE, Bastiaansen BA, van Leerdam ME, et al  Development and validation of the WASP 
classification system for optical diagnosis of adenomas, hyperplastic polyps and sessile serrated 
adenomas/polyps. Dutch Workgroup serrAted polypS & Polyposis (WASP). Gut. 2016 Jun;65(6):963-70. 
34. Lieberman DA, Rex DK, Winawer SJ, et al Guidelines for colonoscopy surveillance after screening and 
polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. United States 
Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012 Sep;143(3):844-57. 
35. Ponugoti, O, Lin, J, Odze, R et al Prevalence of sessile serrated adenoma/polyp in hyperplastic appearing 
diminutive rectosimgoid polyps Gastrointest Endosc 2016; doi.10.1016/j.gie.2016.10.022 
36. Rex KD, Vemulapalli KC, Rex DK;  Recurrence rates after EMR of large sessile serrated polyps. 
Gastrointest Endosc. 2015 Sep;82(3):538-41, 
37. Pellise M, Burgess NG, Tutticci N, et al Endoscopic mucosal resection for large serrated lesions in 
comparison with adenomas: a prospective multicentre study of 2000 lesions. Gut. 2016 Jan 19 
38. Rao AK, Soetikno R, Raju GS, et al Large Sessile Serrated Polyps Can Be Safely and Effectively Removed by 
Endoscopic Mucosal Resection. Clin Gastroenterol Hepatol. 2016 Apr;14(4):568-74 
39. Van Doom, SC, Hazewinkel, Y, East, Je et al Polyp morphology: an interobserver evaluation for the Paris 
classification among international experts Am J Gastroenterol. 2015;110:180-7. doi: 
10.1038/ajg.2014.326  
40. Rex, DK, Helbig CC High yields of small and flat adenomas with high-definition colonoscopes 
using either white light or narrow band imaging.  Gastroenterology 2007; 133: 42-47 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
41. Rex DK  Preventing colorectal cancer and cancer mortality with colonoscopy: what we know and what we 
don't know. See comment in PubMed Commons belowEndoscopy. 2010 Apr;42(4):320-3 
42. Burgess NG, Pellise M, Nanda KS, et al  Clinical and endoscopic predictors of cytological dysplasia or 
cancer in a prospective multicentre study of large sessile serrated adenomas/polyps. Gut. 2016 
Mar;65(3):437-46. gutjnl-2014-308603  
43. Rex DK;  Colonoscopic withdrawal technique is associated with adenoma miss rates. Gastrointest Endosc. 
2000 Jan;51(1):33-6. 
44. Baxter NN1, Warren JL, Barrett MJ, et al  Association between colonoscopy and colorectal cancer 
mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol. 2012 Jul 
20;30(21):2664-9  
45. Nishihara R, Ogino S, Chan AT. Colorectal-cancer incidence and mortality after screening. N Engl J Med. 
2013 Dec 12;369(24):2355 
46. Bassan MS, Cirocco M, Kandel G, et al A second chance at EMR: the avulsion technique to complete 
resection within areas of submucosal fibrosis. Gastrointest Endosc. 2015 Mar;81(3):757. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
 
 
 
Table 1.  The NICE classification 
 
*International NBI Classification (NICE) 
 Type 1 Type 2 Type 3 
Color Same or lighter 
than background 
Browner relative 
to background 
(verify color arises 
from vessels) 
Brown to dark 
brown relative to 
background; 
sometimes patchy 
whiter areas 
Vessels None, or isolated 
lacy vessels may 
be present 
coursing across 
the lesion 
Thick brown 
vessels 
surrounding white 
structures** 
Has area(s) with 
markedly 
distorted or 
missing vessels 
Surface Pattern Dark spots 
surrounded by 
white 
Oval, tubular or 
branched white 
structures** 
surrounded by 
brown vessels 
Distortion or 
absence of 
pattern 
Most likely 
pathology 
Hyperplastic or 
sessile polyp 
(adenoma) 
Adenoma** Deep submucosal 
invasive cancer 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
22 
 
Table 2. Pathology terms we could do without 
 
Confusing Term Better Term 
“carcinoma-in-situ” 
“intramucosal adenocarcinoma” 
High-grade dysplasia 
“sessile serrated adenoma” 
“serrated adenoma” 
Sessile serrated polyp 
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Table 3.  Areas of good and poor agreement between pathologists in colon polyp interpretation 
 
Good agreement 1. Assigning polyps to the conventional adenoma 
vs. serrated class (Figure 1) 
 
2. Identifying submucosal invasion (colon cancer) 
 
Poor agreement 1. Designating dysplasia grade in conventional 
adenomas 
 
2. Determining tubular vs. tubulovillous in 
conventional adenomas 
 
3. Designating serrated class lesions as sessile 
serrated polyp vs. hyperplastic polyp 
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Table 4. The WASP criteria for endoscopic differentiation of sessile serrated polyp from hyperplastic 
polyp 
 
Features that distinguish SSP from HP 
• Irregular surface 
• Indistinct edges 
• Cloud like surface 
• Large open pits 
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Table 5. Implications of granular versus nongranular lateral spreading tumors 
 
Granular –homogeneous type 
         *low risk of cancer (~1%) 
         *low risk of submucosal fibrosis  
 
Granular – mixed nodular type 
          *intermediate risk of cancer (~ 5 %) 
          *higher risk of submucosal fibrosis in the nodular portion 
 
Nongranular 
            *higher risk of cancer (~15%); especially if depressed 
            *higher risk of submucosal fibrosis 
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Table 6. The precancerous colorectal lesions: histology and typical shape, distribution, and relative 
prevalence  
 
Lesion Paris Shape Distribution Prevalence Pathology 
Traditional 
adenomatous 
polyp 
1p 
 
1s 
Left 
 
Throughout 
Low 
 
Common 
Mostly LGD 
 
Mostly LGD 
Flat adenomas 
(lesions) 
2a Greater to right Common Mostly LGD 
Sessile serrated 
adenoma (polyp) 
1s or 2a Right side of colon Common Precancerous but 
distinction from 
HP may not be 
reliable 
TSA 1s or 1p Left side of colon Rare Precancerous 
Depressed 
(adenoma) 
2c 
2a + 2c 
2c + 2a 
Greater to right Rare ↑↑HGD and 
invasive CA 
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Figure legends 
 
Figure 1.  Lesions with NICE Type 3 features indicating deep submucosal invasion.  In 1a most of the lesion shows Type 3 with a 
disrupted amorphous blood vessel pattern.  The yellow line overlies an area of NICE Type 2 features indicating residual intact 
adenoma.  In 1b most of the lesion has NICE Type 2 features but the area surrounded by the yellow line has a disrupted vascular 
pattern consistent with NICE 3 and indicative of deep submucosal invasion. 
Figure 2.  The two major classes of colorectal polyps.   Asterisks denote the precancerous lesions, which include all of the 
conventional adenomas and all of the serrated class lesions except the hyperplastic polyps. 
Figure 3. A sessile serrated polyp (SSP) with cytological dysplasia.  The dysplastic portion of the polyp is the to the upper left.  
To the right is typical non-dysplastic SSP.   
Figure 4. A sessile serrated polyp with cytological dysplasia (same lesion shown in Figure 3).  The arrows point to a brown 
nodule on the polyp surface.  The nodule is the dysplastic portion of the polyp.  
Figure 5. 5a and 5b are typical hyperplastic polyps.  5a and 5b pale from a paucity of blood vessels.  The pits are uniform size 
and either pale (5a) or dark (5b).  The few vessels are thin and lacy. 5c and 5d are sessile serrated polyps.  The yellow line in 5c 
outlines an area of large open pits.  The red line outlines an area with the cloud-like appearance.  The arrow points to an indiscete 
margin and the entire surface has the irregular surface contour of a sessile serrated polyp.  In 5d the arrows outline the indiscrete 
edges of the lesion.  
Figure 6.  The Paris classification.  The Paris type 1 lesion are the polyps.  Type 2 lesions are the flat and depressed lesions.  2a 
and 2 b are flat and 2c and its variants are depressed.   
Figure 7.  7a and 7b are granular lateral spreading tumors (LSTs).  The bumpy surface of thte lesions lead to the “granular” name.  
Granular LSTs have a low risk of invasive cancer and are less likely to demonstrate significant submucosal fibrosis.  7a is a right 
colon lesion about to undergo submucal injection and 7b is a large rectal lesion.  7c is a granular LST with a large nodule.  7d is a 
large transverse colon non-granular LST during the process of resection.  Note the smooth hard appearance of the residual lesion 
that leads to the “non-granular” terminology.  Non-granular LSTs are more likley to have advanced neoplasia including invasive 
cancer and more likley to be technically challenging to remove by endoscopic mucosal resection (EMR) because of submucosal 
fibrosis.  7e shows a small  (13 mm) non-granular LST with a smooth hard appearance and some central depression (black + 
mark).  The arrows point to an edge that is scarred from a previous partial resection.  The lesion was removed by en bloc EMR 
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and demonstrated high-grade dysplasia on pathology.  Figure 7f shows a large nongranular ascending colon LST.  The lesion 
deomonstrated high-grade dysplasia and a tiny focus of invasive adenocarcinoma. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Michael B. Wallace, MD, MPH 
Editor-in-Chief 
John R. Saltzman 
Associate Editor 
on behalf of the GIE Editorial Team 
 
Dear Drs Wallace and Saltzman, 
 
Ref.:   GIE-D-17-00186: The colonoscopist's guide to vocabulary of colorectal neoplasia: histology, 
morphology, and management 
 
We appreciate the reviews of the above named manuscript submitted to GIE.  We have revised the 
manuscript in response to the editors’ comments and the reviews and are now resubmitting the paper 
to GIE.  Below is our point by point response. 
 
Editor's comment: 
 
We thank these authors for a very thorough review. As you can see below, we received diverging peer 
reviews but overall favor publication after revision based on a majority of reviews. I would add to 
comments: 
 
Please add "eligible" to "About 60% of the ELIGIBLE US population report having undergone colonoscopy 
in the last 10 years. Also please consider adding a comment from US NCCN guidelines on management 
of malignant polyps. This will add some additional "weight" to the article and provide some additional 
guideline backed recommendations. 
Thanks for these suggestions.  These have been made, and the NCCN guideline reference was made in 
accordance with your comment below. 
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Change "endoscopist" to "colonoscopist" for consistency. 
 
 
"Thus, an expert colonoscopist is able to differentiate between a serrated and adenomatous polyp..." 
This change was made throughout. 
Under the section 2. The colonoscopist's vocabulary of colorectal cancer, consider 
 
However, these terms are often misinterpreted by patients, referring physicians, and sometimes by 
endoscopists as cancer because they include the word "carcinoma." Current US National Comprehensive 
Cancer Center Network (NCCN) guidelines specifically state, “A malignant polyp is defined as one with 
cancer invading through the muscularis propria and into the submucosa (pT1). PTis is not consider a 
“malignant polyp.”  [https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf]." 
 
Thanks for this excellent suggestion – we added this language. 
 
 
Reviewer #1: 
 
This review aims to describe the vocabulary utilized to categorize the endoscopic and histologic classes 
of colorectal lesions. In addition, the clinical implications of these descriptions is provided. The authors 
also attempt to clear the "confusion" created by the use of some terminology. Indeed the currently used 
terminology creates some confusion and leads to misconceptions, which in turn can lead to misguided 
clinical decisions. Unfortunately, this manuscript creates more confusion rather than clarity. Rather than 
reviewing the literature and describing the currently accepted terminology according to published 
consensus statements and guidelines, the authors provide heavy dose of expert opinion. A substantial 
part of the manuscript criticizes the current status (in most cases appropriately so) and then provides an 
opinion on how to improve things.  In many cases the suggestions are very reasonable yet some lack 
practicality. Advising endoscopist to call their 
pathologist to change the wording of the path report from the currently accepted nomenclature to what 
the authors believe is a better one is probably not the most productive way to deal with the problem. A 
consensus statement supported but GI and pathology experts endorsed on a society level seems to be a 
better way to alter the status quo rather that fighting the battle one pathologist at a time. 
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We changed the specific language of this point about telling the pathologist what terminology to use 
to soften it.   We agree the GI and pathology experts at the society level should meet about this.  
However since the feasibility and likelihood of success of such an effort are uncertain to us we 
decided to keep the general suggestion in place that pathology terms should serve the best interests 
of patients, which they will do by providing clarity.   We feel strongly that including the term 
“carcinoma” in the pathology description of a benign lesion does not facilitate patient care, and we 
kept the general tone of these statements. 
 
Although I agree with most of the authors suggestions, some appear even more confusing than the 
current terminology. For example, instead of Sessile serrated adenoma (SSA)  the term Sessile serrated 
polyp (SSP) is suggested. This does create confusion because many SSA by histology are actually non-
polyoid by morphology. Therefore if for example we are dealing with one of the flat morphologies by 
Paris but the histology is serrated according to the proposed terminology we will have sessile serrated 
polyp that is non-polypoid??? 
 
This is an interesting comment and we added some language to make the reviewer’s point.  However, 
we are not “suggesting” the term “SSP”.  The WHO has already acknowledged the term “SSP” and 
states that is synonymous with “SSA”.  We simply stated that we prefer SSP over SSA because the 
great majority of these lesions are non-dysplastic and most GI docs in our experience do not 
understand that, perhaps because they call them SSAs and adenoma is ingrained in our GI brains as a 
uniformly dysplastic lesion.  The reviewer notes that “SSP” can create confusion because the lesions 
are often flat, and clearly we agree this could create confusion.   Further, both “SSP” and “SSA” 
contain the word “sessile”, which is also now generally used to describe “polyps” rather than flat 
lesions.  So both SSP and SSA could by themselves create shape misunderstanding because of the 
word “sessile.”  We stand by our preference for SSP but have modified this section considerably to 
acknowledge the reviewer’s point that we may be inserting too much of our own opinion.  In 
particular we have converted to the use of SSA/P throughout and emphasized that the terms are each 
accepted, and must be understood as synonymous. 
 
Some important definitions are not provided (what is standard polypectomy?) and some seem 
incomplete (injecting fluid in the sumbmucosa is not mandatory component of EMR). The topic of when 
to utilize EMR or ESD is discussed throughout the text but at the end there is no clarity. That is not 
surprising because the topic as correctly pointed by the authors is controversial but the discussion 
appears heavily angled towards the authors point of view. For example, the most current Japanese 
guidelines discussing the indications for colorectal ESD are not even mentioned or referenced. 
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Rather than standard polypectomy techniques we refer to “standard snaring”.  We did define EMR as 
submucosal injection followed by en bloc or piecemeal snaring, which we think is accurate in the 
colon.  Perhaps submucosal injection is not a necessary part of esophageal EMR, but in the colon EMR 
is generally understood to include injection unless performed underwater.  We modified this language 
slightly to reflect underwater EMR. 
 
 
 
This manuscript will bring a lot of value to initiate a discussion, which hopefully will lead to the creation 
of a "vocabulary" that is accepted by all parties involved. In its current form is mostly an opinion piece 
rather than a review. Most of the statements made are not supported by provided references. 
We tried to be reasonable with referencing.  Admittedly the potential to add references is substantial. 
The editors’ suggestion to add the NCCN website is helpful in this regard.  It appears that all the key 
concepts are referenced. 
 
 
Reviewer #2: 
 
This is a review for practicing gastroenterologists that attempts to provide a lexicon for colonoscopy. 
Although limited to colonoscopy, the review covers many topics which are important. I agree that the 
review is needed. This review has some great images and helpful figures/tables.  I have some specific 
comments for each section: 
1) I think that distinction between ESD and EMR is important but I wonder if the level of detail is 
too much. The purpose of the review is to provide data to practicing gastroenterologists who 
are likely not performing ESD. So perhaps a simple explanation of ESD might suffice. 
We shortened this section considerably. 
2) I have similar thoughts about the section differentiating superficial and deep submucosal 
cancer. Is there too much emphasis on resection of these lesions? 
We think this section is very important because it gets at developing a rationale for ESD.  It would 
detract considerably from creating a state of the art understanding for the reader if we dropped it. 
3) With regards to the serrated pathology section, I think that the flow diagram showing the 
conventional and serrated polyps is great. I would also include in the text a sentence that states 
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that serrated polyps should refer to the group of polyps that includes SSA/Ps, HPs and TSAs and 
that by itself "serrated" does not refer to SSA/Ps. This is a misconception that I see even among 
fellows. If I say to the fellows for example that the polyp looks serrated, meaning HP or SSA/P, 
and they interpret it as SSA/P. 
This is a very good point and we have added material to emphasize this. 
4) The section on polyp morphology is helpful. I would mention the JRSC classification and I would 
also mention that most adenomas we see are IIa (Rex, Helbig Gastro 2007) to put morphology in 
perspective. 
Because the JRSC classification is older than Paris and seldom used, we are reluctant to add it. We 
want to keep the paper as practical and simple as possible, so we prefer to simply use Paris since it is 
most commonly used in clinical practice and in current polyp studies.  We did add a sentence and the 
Rex-Helbig reference to indicate the very high prevalence of flat diminutive lesions in the colon. 
 
 
Reviewer #3: 
 
This manuscript proposes to address areas of confusion in classification of colorectal neoplasia. The 
images provide very helpful illustration of the polyp types. However, in its current version it is primarily 
an "expert opinion" piece rather than a comprehensive review, and provides some recommendations 
which are still considered controversial in our field, without addressing the nuances of why there 
remains uncertainty. Examples of these include: 
1. Assessment of high grade dysplasia and low grade dysplasia for adenomas: many prominent 
pathologists do not believe these are reproducible and have recommended against the routine 
use of these terms. 
We certainly made the point that there is poor interobserver agreement in interpreting dysplasia 
grade by pathologists.  To suggest that they have passed out of use so that are comments are 
irrelevant seems incorrect to us.  In our experience we still commonly see the terms in use in clinical 
practice.  We see them regularly used in clinical studies of colon polyps.  Our guidelines utilize 
dysplasia grade to determine colonoscopy surveillance intervals.  So we have left this discussion in 
place. 
2. Statement that there is high accuracy among pathologists and expert endoscopists in diagnosing 
sessile serrated adenomas: this is a misleading statement. The authors cite their own work but 
fail to cite other publications that have found correlation is poor even among expert 
pathologists. 
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We never said that.  We said that pathologists are fairly accurate in placing polyps within the 
conventional adenoma vs serrated class (which includes both hyperplastic polyps and sessile serrated 
polyps/adenomas.  In fact we devoted quite a bit of language to saying that there was poor 
agreement for classifying lesions within the serrated class (specifically HP vs SSA/P).  We’re quite 
confident that our original language was accurate in these regards. 
3. Resect and discard: the authors argue that resect and discard of small adenomas is a preferred 
strategy but do not acknowledge concerns about generalizability and lack of data on long-term 
outcomes. 
 
 
Actually, we did not argue that resect and discard is preferred.  We consider the topic beyond the 
scope of this paper.  This paper is about endoscopic and histologic correlates and relating terminology 
to clinical concepts.  In this regard it seems appropriate to at least mention that the NICE classification 
and prediction of diminutive polyp pathology forms the basis of the resect and discard paradigm. 
Thus, we only mentioned the resect and discard paradigm. 
4. Implication that endoscopic resection (EMR or ESD) is the preferred strategy vs surgical 
resection: While less invasive resections may be reasonable for some patients, the potential 
limitations of endoscopic resection (eg understaging) and the paucity of long term data on 
recurrence/survival should be specifically discussed to qualify this recommendation. 
We cited a couple of the recent studies that have found that endoscopic resection is associated with 
lower costs and lower morbidity/mortality than surgical resection.  Work from Dr Bourke’s group has 
shown that only 30 patients with large lesions need endoscopic resection to prevent one death from 
surgery.  We believe that the concept of endoscopic resection being preferable to surgery for benign 
lesions is firmly established. 
 
5. "Many SSAs are non-dysplastic" and "Serrated lesions almost universally lack invasive disease" 
are misleading statements and should be qualified/rephrased. 
Certainly the statement “Many SSAs are non-dysplastic” is not misleading.  This is well substantiated 
in many studies.  Only a small percentage of SSAs have cytological dysplasia.   As for invasive disease 
we stated that it is rare to find it in SSAs in the absence of an ulcer or nodule or depression.  We stand 
by that statement and the statement that almost all of them are removable by EMR. 
The manuscript could be strengthened by reformatting into a discussion contrasting new developments 
in the fields of colorectal pathology and endoscopy with the limitations/unanswered questions pertinent 
to each new paradigm/technique. 
Respectfully, this would serve a somewhat different purpose than what we would like to address in 
this paper. 
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We appreciate the comments of the editors and reviewers which have enhanced the manuscript 
substantially, and we hope that the manuscript will now be found suitable for publication in GIE. 
Sincerely, 
Douglas K Rex 
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Acronyms 
CRC Colorectal cancer 
EMR Endoscopic mucosal resection 
ESD Endoscopic submucosal Dissection 
CPT Current Procedural Terminology 
MM Muscularis mucosa 
JNET Japan NBI Expert Team 
NBI Narrow band imaging 
LST Lateral spreading tumor 
NICE NBI International Colorectal Endoscopic Classification 
SSP Sessile serrated polyp 
HP Hyperplastic polyp 
WHO World Health Organization 
NIH National Institutes of Health 
WASP Workgroup serrAted polypS and Polyposis 
ADR Adenoma Detection Rate 
  
  
  
 
